Summary: Therapy-related acute myeloid leukemia (t-AML) has a dismal prognosis and is one of the most frequent second malignant neoplasms which could be encountered by pediatric oncologists. Between October 2000 and September 2016, 16 patients who had primary solid tumors were diagnosed with t-AML at the Seoul National University Children's Hospital. The median patient age at the time of diagnosis of their primary solid tumors was 9.6 years (range, 0.1 to 15.4 y), and that of t-AML was 14.0 years (range, 4.7 to 23.9 y). The median latency period from the end of the primary tumor treatment to the initial diagnosis of t-AML was 29 months (range, 6 to 130 mo). Twelve patients achieved complete remission. Of them, only 7 patients underwent hematopoietic stem cell transplantation (HSCT). The 3-year overall survival (OS) rates and event-free survival rates were 33.7 ± 12.2% and 26.9 ± 11.5% respectively. The patients who underwent HSCT showed favorable 5-year OS rates (57.1 ± 18.7%), whereas the 5-year OS rates of those who did not undergo HSCT was 0%. This study demonstrates that an achievement of complete remission and a subsequent HSCT can be the optimal solution for the treatment of t-AML, and this strategy showed acceptable outcomes.
A secondary malignant neoplasm (SMN) is a second, separate cancer following the original primary neoplasm and it occurs after cancer treatment, such as cytotoxic chemotherapy or radiation therapy for the initial primary malignancy. The number of long-term survivors of cancer is expected to increase because of an improvement in the outcomes of childhood cancers in recent decades. However, this, in turn, could lead to an increase of patients with an SMN.
It is well known that childhood cancer survivors have a 3-fold to 10-fold increased risk of developing an SMN. [1] [2] [3] [4] Among them, therapy-related acute myeloid leukemia (t-AML) has the shortest median latency time and a dismal outcome. 5, 6 For this reason, pediatric oncologists are likely to encounter t-AML or therapy-related myelodysplastic syndrome (t-MDS) more often as an SMN compared with other secondary tumors.
Therapy-related AML and t-MDS both carry dismal prognoses. 7 Although the outcome of t-AML/t-MDS in pediatric patients is better than that it is in adults, 8 5-year event-free survival (EFS) and overall survival (OS) rates of pediatric t-AML/t-MDS have been reported to be 14% to 30%. [9] [10] [11] A study demonstrated a promising 5-year EFS (61.1%) among pediatric t-AML/t-MDS patients who underwent a hematopoietic stem cell transplantation (HSCT). 12 However, higher treatment-related mortality (TRM) rates 9 and disease progression rates 10 render it difficult to overcome the dismal late complication of pediatric cancer survivors.
Certain chemotherapeutic agents have been associated with t-AML/t-MDS. Topoisomerase II inhibitors are known to cause t-AML with MLL gene rearrangements, 8, [13] [14] [15] [16] whereas alkylating agents are more frequently associated with t-AML with aberrations in chromosomes 5 or 7. 8, 17 As these 2 types of chemotherapeutic agents have frequently been used to treat pediatric patients with cancer, t-AML/t-MDS should always be a major concern.
Several studies in children have reported the outcomes of t-AML/t-MDS, in addition to the toxicities and the feasibility of treatments. [9] [10] [11] [12] However, the results are conflicting and overall lacking when compared with those in adults. Therefore, we retrospectively analyzed pediatric patients with t-AML/t-MDS who were treated at the Seoul National University Children's Hospital during a 17-year period. To exclude the possible lineage switch of acute leukemia, 18, 19 only patients whose primary cancers were solid tumors were included in this study.
PATIENTS AND METHODS

Patients
Between October 2000 and September 2016, 16 patients whose primary cancers were solid tumors were diagnosed with t-AML/t-MDS at the Seoul National University Children's Hospital. This study was approved by the Institutional Review Board of the Seoul National University Hospital (H-1208-043-421). The cohort was identified by a retrospective medical record review. Search criteria included age below 18 years at the time of diagnosis of the first solid cancer, and subsequent development of t-AML/t-MDS, which were defined as a new acute myeloid leukemia or myelodysplastic syndrome that developed after the treatment of primary cancer.
Data Collection
Demographic characteristics, data concerning primary cancer, treatments (chemotherapy, radiotherapy, and HSCT), toxicity, and outcome data were collected for all patients by a review of their medical histories. Cumulative doses of chemotherapeutic agents were calculated, and the location and dose of radiation therapy was determined. Chemotherapeutic agents were classified by their mechanisms of action, such as alkylating agents (eg, cyclophosphamide, ifosfamide, melphalan, carboplatin, and cisplatin), topoisomerase 2 inhibitors (eg, etoposide and doxorubicin), and antimetabolites (eg, fluorouracil, methotrexate, and cytarabine). High group of alkylating agents was defined as patients who received a cumulative dose of cyclophosphamide above 20 g/m 2 or of ifosfamide above 40 g/m 2 , or a high dose of chemotherapy with autologous stem cell rescue using busulfan or melphalan. Moreover, the high group of topoisomerase II inhibitor was defined as patients who received a cumulative dose of etoposide above 3. The diagnosis of t-AML and t-MDS was made according to the WHO classification. 20 Therapy-related AML (t-AML) was diagnosed when bone marrow blasts were 20% and over, and t-MDS diagnosed when bone marrow blasts were <20% with a dysplastic lineage if the patient received prior chemotherapy and/or radiotherapy. Cytogenetic analyses were conducted with the trypsinGiemsa banding technique and fluorescent in situ hybridization on bone marrow cells at the time of diagnosis. The latency period was defined as the time from the end of the primary tumor treatment to the diagnosis of t-AML/t-MDS.
Chemotherapy Regimen
Induction chemotherapy was administered to 15 patients, whereas the remaining patient received palliative care due to disease progression. Among the 15 patients, 9 patients received an enocitabine-based regimen was administered once daily as the first dose on day −8, and a targeted dose of busulfan was used according to the therapeutic drug monitoring results on days −7 to −5, 21 whereas the remaining 2 patients received busulfan 30 mg/m 2 once daily for 5 days and 0.8 mg/kg/dose 4 times a day for 4 days. For 6 patients, antithymoglobulin (Thymoglobulin; SangStat, Lyon, France and Genzyme, Cambridge, MA; 2.5 mg/kg once daily IV on days -3 to -1) was administered and etoposide (20 mg/kg once daily IV on days −4 to −2) was administered to 3 patients. One patient who did not receive antithymoglobulin was administered cyclophosphamide (14.5 mg/kg once daily IV on days −3, −2).
Statistical Methods
Categorical variables and continuous variables were compared using the χ 2 test and Student t test, respectively. OS and EFS were analyzed using the Kaplan-Meier method, and the difference in survival rates was determined using the log-rank test. P-values <0.05 were considered statistically significant. Statistical analyses were performed using "R" version 3.2.2 (http://www.r-project.org) and SPSS 20.0 (IBM-SPSS, Armonk, NY).
RESULTS
Characteristics of the Patients and t-AML
Sixteen patients were diagnosed with t-AML between 2000 and 2016. Primary solid tumors in the patients included osteosarcoma (n = 5), neuroblastoma (n = 2), Wilms tumor (n = 2), Ewing sarcoma (n = 2), medulloblastoma (n = 1), pineoblastoma (n = 1), rhabdomyosarcoma (n = 1), anaplastic ependymoma (n = 1), and a malignant germ-cell tumor (n = 1). The median patient age at the time of diagnosis of the primary solid tumors was 9.6 years (range, 0.1 to 15.4 y) and 14.0 years for patients with t-AML (range, 4.7 to 23.9 y). The male-to-female ratio was 1:1. Among them, 3 patients had a family history of cancer. One patient had a sister with Wilms tumor, a mother with mucosa-associated lymphoid tissue lymphoma, and a grandfather with esophageal cancer. The remaining 2 patients had a mother with papillary thyroid cancer and a grandfather with gastric cancer, respectively. There was no patient who met the clinical criteria for Li-Fraumeni syndrome criteria, and TP53 mutations in tumors or germlines could not be investigated in all patients.
Three patients initially presented with t-MDS. The blast counts at the time of diagnosis of t-MDS were 5.3%, Table 2 . Radiation therapy was administered to 7 patients who had intracranial tumors (n = 5), neuroblastoma ( = 1), or Wilms tumor (n = 1). Craniospinal irradiation was administered to 4 patients, with a median dose of 16 Gy (range, 12.2 to 23.4 Gy), and local radiation therapy was administered to 4 patients.
The median latency period from the end of the primary tumor treatment to the time of diagnosis with t-AML/t-MDS was 29 months (range, 6 to 130 mo).
To compare the characteristics of t-AML, the latency period, and survival according to the previous chemotherapy administered, patients were classified as either high or low group of alkylating agents and also for topoisomerase II inhibitors as mentioned above. However, we could not find any differences in age, cytogenetics of t-AML, latency period, and survival between each group, most likely due to the small sample size (Table 3) .
Estimated Incidence Rate of t-AML
To estimate the incidence rate of t-AML in patients with primary solid cancer, we analyzed the patients with solid cancer of Seoul National University Children's Hospital. Between 2004 and 2015, a span of 12 years, a total of 1677 patients with solid cancer were diagnosed. During the same period, 13 patients with t-AML developed from this pool. Although we cannot discount selection bias, considering that some of the patients with t-AML might have visited other hospitals, the crude estimated incidence rate of t-AML from pediatric primary solid cancer was 0.78% (13/1677).
Treatment of t-AML and the Outcome
Fifteen patients received induction chemotherapy after a diagnosis of t-AML. Among them, only 12 patients achieved complete remission (CR). The median time from diagnosis to the achievement of CR was 39 days (range, 16 to 88 d). One patient who did not receive induction chemotherapy and 3 patients who did not achieve CR died due to disease progression and combined complications.
Of the 12 patients who achieved CR, only 7 underwent HSCT (Table 4 ). All 7 patients did not have matched sibling donors, so 4 patients received stem cells from matched ATG indicates antithymocyte globulin; BM, bone marrow; Bu, busulfan; CR, complete remission; Cy, cyclophosphamide; DOD, died of disease; DUCB, double unit cord blood; Flu, fludarabine; HSCT, hematopoietic stem cell transplantation; MUD, matched unrelated donor; PB, peripheral blood; TRM, treatment-related mortality; VP, etoposide. unrelated donors, 2 from double-unit cord blood, and 1 from a haploidentical family donor, respectively. Unfortunately, patients 12 and 14, who received double-unit cord blood transplantations, died of treatment-related complications (the causes were septic shock and cytomegalovirus infection, respectively). Patients 6 and 13 relapsed after HSCT, and patient 6 died of disease progression. However, patient 13 received donor-lymphocyte infusion and is now disease-free. Of the 5 patients who did not receive HSCT although achieved a CR, Patients 1 and 2 received only chemotherapy by patients' selection and relapsed during maintenance chemotherapy after 42.2 and 19.7 months post the first CR, respectively. Patients 8 and 15 died because of early relapse and invasive aspergillosis, respectively. Patient 16 is on consolidation chemotherapy and plans to receive HSCT in the next 2 months.
Overall and Event-free Survival
The OS and EFS rates are displayed in Figure 1 . The 3-year and 5-year OS rates were 33.7 ± 12.2% and 25.2 ± 11.7%, respectively, and the 3-year and 5-year EFS rates were 26.9 ± 11.5% and 20.2 ± 10.4%, respectively. The causes of death were disease progression (n = 8), septic shock (n = 1), cytomegalovirus infection (n = 1), and invasive pulmonary aspergillosis (n = 1). The patients who underwent HSCT showed a favorable 5-year OS rate of 57.1 ± 18.7%, whereas the 5-year OS rate of those who did not undergo HSCT was 0%.
DISCUSSION
Therapy-related AML/t-MDS is a dismal late complication which occurs after cytotoxic chemotherapy and radiotherapy in pediatric patients. In our analysis, the 3-year OS rate of all patients with t-AML was 33.7 ± 12.2%, and that of the patients who underwent HSCT was 57.1 ± 18.7%. These results are superior than the results of earlier studies which reported 3-year OS rates of 15.4 ± 5.8%, 9 14.4 ± 8.0%, 10 and 14.0%. 11 This could be explained because of improvements in leukemia treatment outcomes over the last decade.
This study demonstrated that the achievement of CR and a subsequent HSCT could be the best solution for the treatment of t-AML, which is consistent with previous reports. [9] [10] [11] [12] In our study, patients 1 and 2 achieved CR after induction chemotherapy; however, they refused to receive HSCT and relapsed subsequently at 42.2 and 19.7 months after the achievement of CR, respectively. This finding suggests that chemotherapy alone may not be sufficient for the treatment of t-AML, even though the initial response may be favorable.
A recent study showed 5-year OS rates of 61.1% in pediatric patients with t-AML/t-MDS using HSCT with busulfan, fludarabine, and melphalan as the conditioning regimen and T-cell depleted grafts. 12 Our conditioning regimen with targeted busulfan, fludarabine, and/or etoposide also resulted in a similar outcome. To overcome the large obstacles of the higher probability of poor prognostic cytogenetic features of t-AML 7,10 and a higher tendency of inducing TRM owing to previous cytotoxic therapy 9 , more sophisticated treatment and supportive care, such as a targeted busulfan to reduce organ toxicity 21 or T cell depleted grafts to reduce graft-versus-host disease, 12 are required. Patients 12 and 14 died of infection and other treatmentrelated complications after HSCT. Moreover, patient 15 died of invasive pulmonary aspergillosis after consolidation chemotherapy. The results above suggest that vulnerability to cytotoxic drugs will always remain a concern, which also might be the cause of t-AML/t-MDS.
This study estimated the incidence rate of t-AML in pediatric primary solid cancer as 0.78%. This incidence rate could be meaningful because it was a result of previous chemotherapy and radiotherapy, not by the chance of lineage switching of leukemic cells. [18] [19] However, because of a selection bias as a single center experience, further national or international epidemiologic studies will be necessary.
Recently, in addition to cytogenetic abnormalities, several gene mutations that could serve a role in the pathogenesis of t-AML have been studied, such as point mutations in TP53 or AML1 genes, and mutations in downstream genes in the RAS/BRAF signal-transduction pathway. 22 This has revealed that t-AML is the result of an accumulation of numerous genetic mutations and cytogenetic abnormalities. 23 This process is more complex in adults. 24 A higher incidence of TP53 mutation in t-AML patients has been observed. 25 A recent study revealed that a TP53 mutation found in t-AML cells was also detected at low frequencies at the time of diagnosis of the primary cancer, 3 to 6 years before the development of t-AML/t-MDS. 26 Therefore, a child who already possesses a few TP53 mutated cells could have a higher possibility of developing t-AML or other SMNs. In the future, these susceptible patients may be discovered before the use of cytotoxic therapy using advanced methods such as single cell genomic screening. 27 In summary, we have detailed our experience with pediatric t-AML after the treatment of primary solid tumors. Although there are several obstacles that remain to be overcome, induction chemotherapy for AML and HSCT using targeted busulfan could be an acceptable option. However, the intensity of cytotoxic therapy must be decided according to the medical condition of the patients because of their vulnerability to cytotoxic drugs. Furthermore, screening of susceptible patients by finding out any mutations in the germline predisposing them to t-AML, even at low frequencies, such as TP53 mutations and preventing them from developing t-AML by tailored therapy will be necessary in the future.
